Growth factors and ovarian cancer

1998 ◽  
Vol 5 (4) ◽  
pp. 283-291 ◽  
Author(s):  
S P Langdon
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors

scholarly journals The Importance of Growth Factors and Steroid Hormones in Ovarian Cancer

Onkologie ◽  
2009 ◽  
Vol 32 (11) ◽  
pp. 623-624 ◽  
Author(s):  
Simon P. Langdon ◽  
Dana Faratian ◽  
David J. Harrison
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Steroid Hormones

Urinary excretion of growth factors in patients with ovarian cancer

1994 ◽  
Vol 30 (12) ◽  
pp. 1851-1858 ◽  
Author(s):  
M. Feldkamper ◽  
U. Enderle-Schmitt ◽  
R. Hackenberg ◽  
K.-D. Schulz
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Urinary Excretion

Growth factors in human ovarian cancer

1997 ◽  
Vol 23 (2) ◽  
pp. 113-131 ◽  
Author(s):  
A.M. Westermann ◽  
J.H. Beijnen ◽  
W.H. Moolenaar ◽  
S. Rodenhuis
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Human Ovarian Cancer

scholarly journals Co-Activation of TGFβ and Wnt Signalling Pathways Abrogates EMT in Ovarian Cancer Cells

2017 ◽  
Vol 41 (4) ◽  
pp. 1336-1345 ◽  
Author(s):  
Tulika Mitra ◽  
Sib Sankar Roy
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Wnt Signalling ◽  
Luciferase Assay ◽  
Signalling Pathways ◽  
Ovarian Cancer Cells ◽  
Mesenchymal Transition ◽  
Co Activation

Background/Aims: The aggressive property of ovarian cancer (OC) in terms of epithelial-mesenchymal transition (EMT), proliferation and metastasis are of major concern. Different growth factors including TGFβ are associated with regulating these molecular events but the underlying mechanisms remain unclear. The aim of this report is to decipher the regulation of EMT by co-activation of TGFβ and Wnt signalling cascades in gaining malignancy. Methods: The expression of the different components of signalling events were analyzed by QPCR, Western blot, Immunofluorescence microscopy and flow cytometry. β-catenin promoter activity was checked by luciferase assay. Results: We observed reduced EMT in ovarian cancer cells upon co-activation with TGFβ1 and LiCl as shown by the expressions of epithelial/mesenchymal markers and the EMT promoting factor, Snail1, accompanied by decrease in the invasion and migration of the cells compared to individual pathway activation. A detailed study of the mechanism suggested reduction in the β-catenin and p-GSK3b (Ser 9) levels to be the driving cause of this phenomenon, which was reversed upon co-activation with higher concentrations of LiCl. Conclusions: Therefore, tumourigenesis might be affected by the concentration of ligand/ growth factors for the respective signalling pathways activated in the tumour microenvironment and interaction between them might alter tumourigenesis.

scholarly journals Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts

2007 ◽  
Vol 16 (8) ◽  
pp. 1691-1695 ◽  
Author(s):  
Shelley S. Tworoger ◽  
I-Min Lee ◽  
Julie E. Buring ◽  
Michael N. Pollak ◽  
Susan E. Hankinson
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Ovarian Cancer Risk ◽  
Nested Case Control ◽  
Control Study ◽  
Insulin Like Growth Factors

Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer

2016 ◽  
Vol 26 (5) ◽  
pp. 574-583 ◽  
Author(s):  
Insiya B. Poonawalla ◽  
Linda B. Piller ◽  
David R. Lairson ◽  
Wenyaw Chan ◽  
Xianglin L. Du
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Elderly Patients ◽  
Advanced Ovarian Cancer ◽  
Hematopoietic Growth Factors

Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy

2018 ◽  
Author(s):  
Anca Maria Cimpean ◽  
Andreea Adriana Jitariu ◽  
Marius Raica
Keyword(s):  
Ovarian Cancer ◽  
Growth Factors ◽  
Growth Factor ◽  
Disease Free Survival ◽  
Endocrine Gland ◽  
Vascular Endothelial ◽  
Free Survival ◽  
Ovarian Carcinogenesis ◽  
Endothelial Growth Factor

Ovarian cancer remains one of the most aggressive and difficult to manage malignancies regarding evaluation and therapeutic options. The high mortality persists despite extensive research in the field. Current conventional chemotherapy does not improve disease-free survival and does not decrease recurrences amongst patients. This calls for a stringent reconsideration of the drugs selection, focused on the most targeted strategies and personalization of the therapy. Targeted agents against growth factors and their corresponding receptors are already approved as first- or second-line neoadjuvant therapy with controversial results. This chapter critically discusses the role of growth factors as vascular endothelial growth factor, fibroblast growth factors, or platelet-derived growth factors and their corresponding receptors in the pathogenesis, progression, and selection of therapeutic strategies. Other growth factors, such as nerve growth factor or endocrine gland derived growth factor, seem to have a strong involvement in ovarian carcinogenesis but their actual impact is not fully understood.

Sign in / Sign up

Export Citation Format

Share Document